Highlights Newsletter 4

This newsletter presents you the following key sessions:

1. Podcast with prof. dr. Jean Luc van Laethem about the KEYNOTE 224 trial: phase II study evaluating
    pembrolizumab monotherapy

2. Ipilimumab, nivolumab and panitumumab for chemorefractory KRAS/NRAS/BRAF wild type,
    microsatellite stable metastatic colorectal cancer

3. Impact of neoadjuvant therapies on the risk for perioperative complications in patients with advanced
    thoracic oesophageal cancer

4. Trifluridine/tipiracil provides the greatest clinical benefit when used in the third-line treatment of
    patients with metastatic gastric cancer

5. The FGFR-selective tyrosine kinase inhibitor infigratinib shows promising efficacy in patients advanced
    cholangiocarcinoma harbouring FGFR2 alterations